ClinicalTrials.Veeva

Menu

Complications and Adverse Events in Lymphadenectomy in the Inguinal Area

University of Southern California logo

University of Southern California

Status

Invitation-only

Conditions

Consensus Development

Treatments

Behavioral: Delphi Questionnaire

Study type

Observational

Funder types

Other

Identifiers

NCT05388786
UP-22-00368

Details and patient eligibility

About

The investigators aim to create an effective and accurate method to report, define, and classify complications and adverse events during and after Inguinal lymph node dissection (ILND) as part of the staging and treatment for penile cancer, vulvar cancer, and melanoma. In turn, this will become an objective, efficient, and reproducible tool to facilitate comparisons across surgical approaches, techniques, and surgeons.

Full description

Inguinal lymph node dissection (ILND) has shown to be a necessary surgery from the oncology standpoint being extensively used as part of the staging process in malignancies of the penis, vulva, or melanoma. Moreover, the ILND has been shown to improve survival if performed in a timely manner. Yet, ILND is linked to a high rate of complications and adverse events.

Complications and adverse events' incidence are frequently used as surrogate markers of quality in surgery. However, there is tremendous heterogeneity in the report in such specifically for this procedure. Even though different classification and grading systems on surgical complications are available. There is a lack of standardization regarding the definition and classification to report ILND complications and adverse events leading to discrepancies across the literature, often interfering with the interpretation of surgical performance and quality.

This study will provide a systematic definition and classification of ILND complications and adverse events, ultimately improving the reporting of such conditions for future studies.

To create an effective and accurate method to report, define, and classify complications and adverse events during and after ILND as part of the staging and treatment for penile cancer, vulvar cancer, and melanoma. In turn, this will become an objective, efficient, and reproducible tool to facilitate comparisons across surgical approaches, techniques, and surgeons.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Experts in open inguinal lymphadenectomy
  • Experts in video endoscopic inguinal lymphadenectomy (VEIL)
  • Experts in robotic video endoscopic inguinal lymphadenectomy (R-VEIL)
  • Authors with at least one publication in ILND for penile cancer, vulvar cancer, or melanoma

Exclusion criteria

  • Panelists who were not able to commit to all rounds of the modified Delphi process will be excluded

Trial design

200 participants in 1 patient group

Delphi Panel
Description:
A team of experts in open inguinal lymphadenectomy, video endoscopic inguinal lymphadenectomy (VEIL), and robotic-assisted video endoscopic inguinal lymphadenectomy (R-VEIL) in the fields of General Surgery, Gynecology Oncology, Surgical Oncology, and Urology will be invited to participate. These experts are identified according to surgical experience, research, and academic interest.
Treatment:
Behavioral: Delphi Questionnaire

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems